The FDA has removed the recommended pause in the use of Valneva’s chikungunya vaccine Ixchiq in individuals aged 60 years and older.

The Ixchiq vaccine was approved for adults 18 and up at risk of exposure to the virus in 2023, when the CDC had recorded 152 ...